Bone health and glucocorticoid‐containing lymphoma therapy — a review of risk factors and preventative measures
Abstract With survival outcomes ever improving for patients with a wide range of lymphoma histologies, the focus on reducing long‐term complications of therapy has increased. Recently published, complimentary population and retrospective series have highlighted the importance of considering bone health in patients treated for lymphoma. Fracture‐related events or the requirement for secondary bone prophylaxis, likely linked to glucocorticoid‐induced osteoporosis (GIO) are substantial and clinically meaningful in a significant minority of patients following routinely employed steroid‐containing immunochemotherapy. In this review, we describe the pathophysiology of GIO, the risk of GIO in observational front‐line lymphoma studies and efficacy of prophylactic measures from several prospective clinical trials are summarized. Finally, areas of importance for future research are discussed and recommendations for GIO risk assessment and management in lymphoma are provided based on the current available literature..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:198 |
|---|---|
| Enthalten in: |
British Journal of Haematology - 198(2022), 3, Seite 431-442 |
| Beteiligte Personen: |
Eyre, Toby A. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 British Society for Haematology and John Wiley & Sons Ltd |
|---|
| Umfang: |
12 |
|---|
| doi: |
10.1111/bjh.18104 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002828146 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002828146 | ||
| 003 | DE-627 | ||
| 005 | 20230307122217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/bjh.18104 |2 doi | |
| 028 | 5 | 2 | |a BJH_BJH18104.xml |
| 035 | |a (DE-627)WLY002828146 | ||
| 035 | |a (WILEY)BJH18104 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.86 |2 bkl | ||
| 100 | 1 | |a Eyre, Toby A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bone health and glucocorticoid‐containing lymphoma therapy — a review of risk factors and preventative measures |
| 264 | 1 | |c 2022 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 British Society for Haematology and John Wiley & Sons Ltd | ||
| 520 | |a Abstract With survival outcomes ever improving for patients with a wide range of lymphoma histologies, the focus on reducing long‐term complications of therapy has increased. Recently published, complimentary population and retrospective series have highlighted the importance of considering bone health in patients treated for lymphoma. Fracture‐related events or the requirement for secondary bone prophylaxis, likely linked to glucocorticoid‐induced osteoporosis (GIO) are substantial and clinically meaningful in a significant minority of patients following routinely employed steroid‐containing immunochemotherapy. In this review, we describe the pathophysiology of GIO, the risk of GIO in observational front‐line lymphoma studies and efficacy of prophylactic measures from several prospective clinical trials are summarized. Finally, areas of importance for future research are discussed and recommendations for GIO risk assessment and management in lymphoma are provided based on the current available literature. | ||
| 700 | 1 | |a Jensen, Paw |4 aut | |
| 700 | 1 | |a Booth, Stephen |4 aut | |
| 700 | 1 | |a El‐Galaly, Tarec Christoffer |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British Journal of Haematology |g 198(2022), 3, Seite 431-442 |w (DE-627)WLY002803046 |x 13652141 |7 nnns |
| 773 | 1 | 8 | |g volume:198 |g year:2022 |g number:3 |g pages:431-442 |g extent:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.86 |q ASE |
| 951 | |a AR | ||
| 952 | |d 198 |j 2022 |e 3 |h 431-442 |g 12 | ||